Indacaterol

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 8, Issue 5, 2011, Pages 327-328

  Donohue, James F ^a   Martinez, Fernando J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

INDACATEROL; PLACEBO; TIOTROPIUM BROMIDE;

CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG APPROVAL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; HUMAN; INSPIRATORY CAPACITY; LUNG EMPHYSEMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; HUMANS; INDANS; INSPIRATORY CAPACITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES;

EID: 80053083243     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2011.615629     Document Type: Editorial

References (13)

1. Beeh KM, Wagner F, Khindri S, et al. Effect of Indacaterol on Dynamic Lung Hyperinflation and Breathlessness in Hyperinflated Patients with COPD. COPD 2011; July 17.
2. O'Donnell, DE. Casaburi R, Vincken, W, et al. Efect of Inda-caterol on Exercise Endurance and Lung Hyperinfation in COPD. Respiratory Medicine 2011; 105(7):1030-6.
3. Dahl, R, Chung KF, Buhl R, et al. Efcacy of a New Once-Daily Long-Acting Inhaled Beta 2-Agonist Indacaterol versus Twice-Daily Formoterol in COPD. Torax 2010; 65(6):473-9.
4. Kornmann, O, Dahl E, Centanni S, et al. Once-Daily Indacaterol versus Twice-Daily Salmeterol for COPD: a Placebo-Controlled Comparison. Eur Respir J 2011; 37(2):273-9.
5. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD Pharmacological Trials: From Lung Function to Biomarkers. Eur Respir J 2008; 31(2):416-69.
6. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). NDA 22-383 Briefng Document. At: http://www.fda. gov/downloads/AdvisoryCommittees/CommitteesMeetingMat- erials/Drugs/Pulmonary-AllerfgyDrugsAdvisoryCommittee/UCM245639.pdf [accessed 8 June 2011].
7. Donohue JF, Fogarty C. Lotvall C, et al. Once-Daily Bronchodila-tors for Chronic Obstructive Pulmonary Disease: Indacaterol versus Tiotropium. Am J Respir Crit Care Med 2010; 182:155-162.
8. Barnes PJ, Pocock SJ, Magnussen H, et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ter. 2010 Jun; 23(3):165-71. Epub 2010 Jan 18.
9. Renard D, Looby M, Kramer B, et al. Characterization of the Bronchodilatory Dose Response to Indacaterol in Patients with Chronic Obstructive Pulmonary Disease using Model-Based Approaches. Respir Res. 2011 April 26; 12:54.
10. Toy EL, Beaulieu NU, McHale JM, et al. Treatment ofCOPD: Relationships between Daily Dosing Frequency, Adherence, Resource Use and Costs. Respir Med 2011 Mar; 105(3):435-41.
11. Wang J, Nie B, Xiong W, et al. Efect of Long Acting Beta Agonists on the Frequency of COPD Exacerbations: A Meta-Analysis. J Clin Pharm Ter. 2011 Jul 11. doi: 10.1111/j.1365-2710.2011.01285.x.
12. Buhl R, Dunn LJ, Disdier C, et al. Blinded 12 week Comparison of Once-Daily Indacaterol and Tiotropium in COPD. Eur Respir J 2011, May 26.
13. Donohue JF, Singh D, Kornmann O, et al. Safety of Indacaterol in the Treatment of Patients with COPD International J of COPD. 2011; accepted.